乐天堂fun88

Wang Deping, Academician of the National Academy of Engineering of Ukraine, and Zhang Boqing, Chairman of Beroni Group, led a delegation to the visit Shenzhen Cell Valley

Date:12-09  Hits:  Belong to:News & Events


December 6,Researcher Wang Deping, Former Director of the China National Biotechnology Development Center of the Ministry of Science and Technology and Academician of the Ukrainian National Academy of Engineering, Chairman Zhang Boqing and Vice President Zhang Lei of Beroni Group visited Shenzhen Cell Valley.Professor Shi Yuanyuan, Chairman of our company, together with Commercial Director Wei Zheng and Office Director Wang Lu, extended a warm reception to the delegation.This visit focused on future cell industry policies, aiming to deepen strategic cooperation through the strong alliance of both parties and jointly promote the innovative development of the cell industry. 



Through the detailed introduction by Business Director Wei Zheng, Academician Wang and his delegation visited the Shenzhen Cell Valley Intelligent Digital Exhibition Hall, as well as the production, quality management laboratory, and R&D center, gaining a deeper and more comprehensive understanding of the comprehensive and one-stop service system provided by Shenzhen Cell Valley.


During the symposium, Professor Shi Yuanyuan elaborated on the leading position and market prospects of Shenzhen Cell Valley in cell therapy technology. He stated that Shenzhen Cell Valley, leveraging its core competencies such as industrialized production processes, has provided high-standard and highly safe cell preparation services to numerous tertiary hospitals in China. Meanwhile, Cell Valley has not only continuously expanded its presence in the domestic market but also successfully extended its business to overseas markets, achieving critical breakthroughs in regional markets. Shenzhen Cell Valley consistently upholds the mission values of "Cells Benefit All, Genes Create the Future," dedicated to transforming cell therapy technology from basic scientific research into practical clinical applications, delivering innovative treatment solutions to patients across various regions.


At the meeting, Academician Wang Deping and Chairman Zhang Boqing mentioned that multiple cities, including Tianjin, have successively issued regulations to promote the gene and cell industry, comprehensively covering the entire industrial chain, including cell collection and storage, research and clinical trials, expanded use and clinical trials, and application production. The government actively guides leading enterprises to strengthen collaboration with research institutions and medical institutions through various means such as capital injection and technology equity participation, jointly driving the innovative development of gene and cell technologies and products. This visit aims to explore further cooperation opportunities between the two regions under the framework of cell industry policies by gaining an in-depth understanding of the technical and service systems of Shenzhen Cell Valley, achieving resource sharing and complementary advantages, and jointly promoting the high-quality development of the cell and gene industry.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@wfzydp.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a leading one-stop comprehensive outsourcing service provider for China’s cell and gene therapy industry. It is also among the first domestic CRO/CDMO enterprises to hold GMP-compliant industrial production capabilities for clinical-grade retroviral vectors. As a key project for the construction of Shenzhen’s public technical service platform for CRO/CDMO, the company has been listed in the city’s newly announced "20+8" strategic emerging industries initiative.
Shenzhen Cell Valley is equipped with the capacity to conduct standardized and industrialized production of GMP-grade cellular products including CAR-T cells. Its core production lines cover a full spectrum of cellular products such as CAR-T, CAR-NK, CAR-M, γδT, TIL and TCR-T. In addition, the company runs production lines for a diverse range of viral vectors (including RVV, LVV and AAV) and non-viral vectors, as well as for cellular raw materials for therapeutic development—such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software